Treatment of chronic hepatitis C with direct-acting antivirals in patients with β-thalassaemia major and advanced liver disease

التفاصيل البيبلوغرافية
العنوان: Treatment of chronic hepatitis C with direct-acting antivirals in patients with β-thalassaemia major and advanced liver disease
المؤلفون: Sinakos, E. Kountouras, D. Koskinas, J. Zachou, K. Karatapanis, S. Triantos, C. Vassiliadis, T. Goulis, I. Kourakli, A. Vlachaki, E. Toli, B. Tampaki, M. Arvaniti, P. Tsiaoussis, G. Bellou, A. Kattamis, A. Maragkos, K. Petropoulou, F. Dalekos, G.N. Akriviadis, E. Papatheodoridis, G.V.
سنة النشر: 2017
الوصف: Interferon-based regimens for chronic hepatitis C (CHC) were often deferred in patients with β-thalasaemia major (β-TM) due to poor efficacy and tolerance. Current guidelines recommend direct-acting antivirals (DAAs) for these patients. The aim of this study was to assess the safety and efficacy of DAAs in patients with β-TM and advanced liver disease due to CHC. Patients were recruited from eight liver units in Greece. The stage of liver disease was assessed using transient elastography and/or liver histology. Five regimens were used: sofosbuvir (SOF) + ribavirin (RBV); SOF + simeprevir ± RBV; SOF + daclatasvir ± RBV; ledipasvir/SOF ± RBV and ombitasvir/paritaprevir-ritonavir + dasabuvir ± RBV. Sixty-one patients (median age 43 years) were included. The majority of patients was previously treated for hepatitis C (75%) and had cirrhosis (79%). Viral genotype distribution was: G1a: n = 10 (16%); G1b: n = 22 (36%); G2: n = 2 (3%); G3: n = 14 (23%); G4: n = 13 (22%). The predominant chelation therapy was a combination of deferoxamine and deferiprone (35%). Overall sustained virological response rates were 90%. All treatment regimens were well tolerated and no major adverse events or drug-drug interactions were observed. Approximately half of the patients who received RBV (7/16, 44%) had increased needs for blood transfusion. Treatment of CHC with DAAs in patients with β-TM and advanced liver disease was highly effective and safe. © 2017 John Wiley & Sons Ltd
اللغة: English
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=od______2127::316ae958786f3b151229b4867761c669Test
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3108562Test
حقوق: OPEN
رقم الانضمام: edsair.od......2127..316ae958786f3b151229b4867761c669
قاعدة البيانات: OpenAIRE